Neuroimmune mechanisms in cancer pain

Current Opinion in Supportive and Palliative Care

Volumn 9, Issue 2, 2015, Pages 103-111

  Brown, Matthew R D ^a,b   Ramirez, Juan D ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cancer; graft versus host disease; neuroimmune; pain

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE PAIN; BONE TUMOR; CELLULAR IMMUNITY; CHEMICALLY INDUCED; DRUG EFFECTS; GRAFT VS HOST DISEASE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASMS; NEURALGIA; PAIN, POSTOPERATIVE; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PHYSIOLOGY; SECONDARY; SIGNAL TRANSDUCTION;

ACUTE PAIN; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; NEURALGIA; NEUROIMMUNOMODULATION; PAIN, POSTOPERATIVE; PERIPHERAL NERVOUS SYSTEM; SIGNAL TRANSDUCTION;

EID: 84946161780     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000140     Document Type: Review

References (98)

1. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci 2005; 6:521-532.
2. Ellis A, Bennett DLH. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth 2013; 111:26-37.
3. Schmidt BL. The neurobiology of cancer pain. Neuroscientist 2014; 20:546-562.
4. Perentes JY, Duda DG, Jain RK. Visualizing antitumor immune responses in vivo. Dis Model Mech 2009; 2:107-110.
5. Tarin D. Role of the host stroma in cancer and its therapeutic significance. Cancer Metastasis Rev 2013; 32:553-566.
6. Servais C, Erez N. From sentinel cells to inflammatory culprits: cancerassociated fibroblasts in tumour-related inflammation. J Pathol 2013; 229: 198-207.
7. Gooden MJM, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with metaanalysis. Br J Cancer 2011; 105:93-103.
8. Le Bitoux M-A, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol 2008; 130:1079-1090.
9. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002; 2:201-209.
10. Haymond T, Smith SN, Sweitzer SM. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J Pain Symptom Manage 2014; 7:531-545.
11. Shiao SL, Preethi Ganesan A, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011; 25:2559-2572.
12. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2011; 140:883-899.
13. Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13:759-771.
14. Al-Husari M, Webb SD. Theoretical predictions of lactate and hydrogen ion distributions in tumours. PLoS One 2013; (8) DOI: 10.1371/journal.pone. 0072020.
15. Vanhecke E, Adriaenssens E, Verbeke S, et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res 2011; 17:1741-1752.
16. Okugawa Y, Tanaka K, Inoue Y, et al. Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. Br J Cancer 2013; 108:121-130.
17. Tanaka K, Okugawa Y, Toiyama Y, et al. Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One 2014; 9:e96410.
18. Shonukan O, Bagayogo I, McCrea P, et al. Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin. Oncogene 2003; 22:3616-3623.
19. Ricci A, Greco S, Mariotta S, et al. Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 2001; 25:439-446.
20. Wörmann SM, Algül H. Risk factors and therapeutic targets in pancreatic cancer. Front Oncol 2013; 3:282; DOI: 10.3389/fonc.2013.00282.
21. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003; 4:299-309.
22. Entschladen F, Palm D, Lang K, et al. Neoneurogenesis: Tumors may initiate their own innervation by the release of neurotrophic factors in analogy to lymphangiogenesis and neoangiogenesis. Med Hypotheses 2006; 67:33-35.
23. Werner MU, Kongsgaard UEI. Defining persistent postsurgical pain: is an update required? Br J Anaesth 2014; 113:1-4.
24. Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med 2014; 6:265-6.
25. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997; 276:75-81.
26. Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth 2010; 105 (Suppl):i69-i85.
27. Uçeyler N, Schäfers M, Sommer C. Mode of action of cytokines on nociceptive neurons. Exp brain Res 2009; 196:67-78.
28. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002; 302:839-845.
29. Macrae WA. Chronic postsurgical pain: 10 years on. Br J Anaesth 2008; 101:77-86.
30. Kalso E. Persistent postsurgery pain: research agenda for mechanisms, prevention, and treatment. Br J Anaesth 2013; 111:9-12.
31. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med 2010; 16:1267-1276.
32. Reichling DB, Green PG, Levine JD. The fundamental unit of pain is the cell. Pain 2013; 154 (Suppl):S2-S9.
33. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152:S2-S15.
34. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001; 8:1-10.
35. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353:2051-2058.
36. Ji R-R, Xu Z-Z, Gao Y-J. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 2014; 13:533-548.
37. Ikeda H, Kiritoshi T, Murase K. Contribution of microglia and astrocytes to the central sensitization, inflammatory and neuropathic pain in the juvenile rat. Mol Pain 2012; 8:43.
38. Taves S, Berta T, Chen G, Ji RR. Microglia and spinal cord synaptic plasticity in persistent pain. Neural Plast 2013; DOI: 10.1155/2013/753656.
39. Calvo M, Bennett DLH. The mechanisms of microgliosis and pain following peripheral nerve injury. Exp Neurol 2012; 234:271-282.
40. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765-1769.
41. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013; 63: 419-437.
42. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72:151-169.
43. Herskovits S, Schaumburg HH. Neuropathy caused by drugs. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. Elsevier; 2005. pp. 2553-2583.
44. Brown MR, Ramirez JD, Farquhar-Smith P. Pain in cancer survivors. Br J Pain 2014; 8:139-153.
45. Bennett GJ, Doyle T, Salvemini D. Mitotoxicity in distal symmetrical sensory peripheral neuropathies. Nat Rev Neurol 2014; doi:10.1038/nrneurol. 2014.77.
46. LaPointe NE, Morfini G, Brady ST, et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013; 37:231-239.
47. Peters CM, Jimenez-Andrade JM, Kuskowski M, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007; 1168:46-59.
48. Warwick R, Hanani M. The contribution of satellite glial cells to chemotherapyinduced neuropathic pain. Eur J Pain 2013; 17:571-580.
49. Yoon S-Y, Robinson CR, Zhang H, Dougherty PM. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. J Pain 2013; 14:205-214.
50. Cavaletti G, Cornblath DR, Merkies ISJ, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24:454-462.
51. Wang X-M, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012; 59:3-9.
52. Alaedini A, Xiang Z, Kim H, et al. Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol 2008; 210:368-374.
53. Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol 2013; 4:156.
54. Jin HW, Flatters SJL, Xiao WH, et al. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 2008; 210:229-237.
55. Siau C, Xiao W, Bennett GJ. Paclitaxel-and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006; 201:507-514.
56. Dauch JR, Bender DE, Luna-Wong LA, et al. Neurogenic factor-induced Langerhans cell activation in diabetic mice with mechanical allodynia. J Neuroinflammation 2013; 10:64.
57. Casanova-Molla J, Morales M, Planas-Rigol E, et al. Epidermal Langerhans cells in small fiber neuropathies. Pain 2012; 153:982-989.
58. Piccione EA, Engelstad J, Wieland C, Klein CJ. Langerhans cell activation in diabetic small fiber polyneuropathy. Neurol Neuroimmunol Neuroinflammation 2014; 1:e42-e142.
59. Smith EEML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309:1359-1367.
60. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2014; 32:1941-1967.
61. Brigo F, Balter R, Marradi P, et al. Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia. J Child Neurol 2012; 27:867-874.
62. Ferrara J, Levine J, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-1561.
63. Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med 2013; 2:25-32.
64. Haruki H, Ogasawara J, Omoto M, et al. Neuropathy in chronic graft-versushost disease caused by donor T cells. Muscle Nerve 2012; 46:610-611.
65. Doi Y, Sugahara H, Yamamoto K, et al. Immune-mediated peripheral neuropathy occurring simultaneously with recurrent graft-versus-host disease after allogenic hematopoietic stem cell transplantation. Leuk Res 2012; 36:e63-e65.
66. Kraus PD, Wolff D, Grauer O, et al. Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graftversus-host disease. PLoS One 2012; 7:e44922.
67. Thöne J, Lamprecht S, Hohaus A, et al. Guillain-Barré syndrome as leading manifestation of graft-versus-host disease in an allogeneic bone marrow transplanted patient. J Neurol Sci 2010; 292:114-116.
68. Lorenzoni PJ, Scola RH, Carsten AL, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: case report. Arq Neuropsiquiatr 2007; 65:700-704.
69. Kamble RT, Chang C-C, Sanchez S, Carrum G. Central nervous system graftversus-host disease: report of two cases and literature review. Bone Marrow Transplant 2007; 39:49-52.
70. Grauer O, Wolff D, Bertz H, et al. Neurological manifestations of chronic graftversus-host disease after allogeneic haematopoietic stem cell transplantation: Report from the consensus conference on clinical practice in chronic graftversus-host disease. Brain 2010; 133:2852-2865.
71. Barba P, Pinaña JL, Valcárcel D, et al. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1439-1446.
72. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593.
73. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
74. Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 2014; 32:1647-1654.
75. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 2004; 18:267-274.
76. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 2006; 3:41-49.
77. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11:411-425.
78. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12:6213s-6216s.
79. Simmons CPL, Macleod N, Laird BJA. Clinical management of pain in advanced lung cancer. Clin Med Insights Oncol 2012; 6:331-346.
80. Mach D, Rogers S, Sabino M, et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002; 113:155-166.
81. Assas BM, Pennock JI, Miyan JA. Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. Front Neurosci 2014; 8:23.
82. Jimenez-Andrade JM, Bloom AP, Stake JI, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 2010; 30:14649-14656.
83. Jimenez-Andrade JM, Ghilardi JR, Castañeda-Corral G, et al. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain 2011; 152: 2564-2574.
84. Muralidharan A, Smith MT. Pathobiology and management of prostate cancerinduced bone pain: recent insights and future treatments. Inflammopharmacology 2013; 21:339-363.
85. Falk S, Uldall M, Heegaard A-M. The role of purinergic receptors in cancerinduced bone pain. J Osteoporos 2012; 2012:758181.
86. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139:267-284.
87. Honoré P, Schwei J, Rogers SD, et al. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res 2000; 129:389-397.
88. Doré-Savard L, Otis V, Belleville K, et al. Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PLoS One 2010; 5:e13774.
89. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000; 98:585-598.
90. Liu X-D, Yang J-J, Fang D, et al. Functional upregulation of nav1.8 sodium channels on the membrane of dorsal root ganglia neurons contributes to the development of cancer-induced bone pain. PLoS One 2014; 9:e114623.
91. Yanagisawa Y, Furue H, Kawamata T, et al. Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord. Mol Pain 2010; 6:38.
92. Donovan-Rodriguez T, Dickenson AH, Urch CE. Superficial dorsal horn neuronal responses and the emergence of behavioural hyperalgesia in a rat model of cancer-induced bone pain. Neurosci Lett 2004; 360:29-32.
93. Kane CM, Hoskin P, Bennett M. Cancer induced bone pain. Br Med J 2015; 315:1-8.
94. Wang X, Yang KH, Wanyan P, Tian JH. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett 2014; 7:1997-2002.
95. Bloom AP, Jimenez-Andrade JM, Taylor RN, et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain 2011; 12:698-711.
96. Kumar V, Mahal B. NGF-The TrkA to successful pain treatment. J Pain Res 2012; 5:279-287.
97. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-327.
98. Pichler WJ. Adverse side-effects to biological agents. Allergy Eur J Allergy Clin Immunol 2006; 61:912-920.